Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Elicio Therapeutics Inc

ELTX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$3.09

▼ -1.90%

Market Cap $81.21M · Vol 36.68K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$81.21M

Micro Cap

Div Yield

N/A

EPS Growth

+23.26%

YoY

RSI (14)

54.21

Momentum

Beta

1.35

vs Market

52W High

$16.00

80.69% below

52W Low

$2.67

15.73% above

Volume

36.68K

Avg 130.36K

P/B

86.61

Price-to-book

ROE

N/A

Return on equity

Free Float

68.86%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Elicio Therapeutics Inc (ELTX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ELTX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.13%

-0.64%

-71.65%

-63.86%

YTD

-61.18%

-68.91%

-69.10%

-97.21%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-39,571,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-146.45% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	86.61
P/FCF	N/A
EPS Growth	+23.26%
Outstanding Shares	26.28M

Technical Indicators

50-Day SMA	$4.86
200-Day SMA	$8.49
RSI (14)	54.21
Beta	1.35
52-Week High	$16.00
52-Week Low	$2.67

Volume Today	36.68K
Avg Daily Volume (30D)	130.36K
Relative Volume	0.28x
Volatility (10D)	56.27
Volatility (30D)	93.54
Free Float	68.86%

Analyst Consensus

BUY

Current Price $3.09

Mean Target $20.00

52W Low$2.67 52W High$16.00

Current

Target

$2.67 $16.00

Current Analyst target

+547.25% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00444GM11

ISINUS28657F1030

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.